Sono Bello Funding, Investors & Competitors

Sono Bello has raised $611M across 2 funding rounds, most recently a $546M undisclosed-stage round in February 2023.

Last Sono Bello funding round

$546M

Undisclosed stage · Feb 2023

Cumulative funding Sono Bello raised

$611M

across 2 funding rounds

Key investors in Sono Bello

Sono Bello Overview

About Sono Bello

Sono Bello is a nationwide network of surgical centers specializing in laser-assisted liposuction and body contouring. Scottsdale-headquartered Sono Bello operates over 100 locations across the US, performing procedures like TriSculpt and AirSculpt. Board-certified surgeons customize treatments for abdomen, thighs, and arms. Sono Bello established its first center in 2011.


Founded

2012

HQ

United StatesSeattle, WA

Status

Privately held

Customer focus

B2C

Revenue model

Services

Sono Bello Funding History

Sono Bello has raised a total of $611M across 2 funding rounds.

Sono Bello's first fundraising round was a $65M undisclosed-stage round in March 2022. The most recent completed round was a $546M undisclosed-stage round in February 2023.

Sono Bello funding rounds

Sono Bello funding rounds
DateStageInvestorsRaisedDeal Summary
Feb 2023Undisclosed stageAlaris Equity Partners (lead); Brookfield Asset Management (lead)$546MSono Bello, operating as Body Contour Centers LLC (BCC), is a leading provider of body contouring procedures through a nationwide network of surgical centers staffed by board-certified surgeons, targeting everyday customers with accessible pricing and services accredited by the Accreditation Association for Ambulatory Health Care. On February 14, 2023, Alaris Equity Partners, already an investor since 2018, completed a strategic transaction with Brookfield Special Investments, involving Alaris exchanging US$145.0 million of existing preferred units for newly issued convertible preferred units and Brookfield investing approximately US$400.0 million for newly created convertible preferred units, plus Alaris receiving US$20.3 million cash from redemption of remaining existing units, totaling a US$546 million strategic investment referenced in announcements. This enabled Alaris to increase its stake, provide partial liquidity to management, and support growth, while partnering with Brookfield for additional expertise and capital to expand across North America. Alaris realized a US$9.3 million premium on the redemption of its existing preferred units, which had an initial cost of US$156.3 million, highlighting the transaction's value extraction. The new convertible preferred units allow Alaris conversion to common equity before the fifth anniversary, participation in equity upside, plus an annual transaction fee and potential profit participation if performance thresholds are met, enhancing expected returns. The deal confirmed Sono Bello as a high-performing asset, maintaining Alaris' run rate payout ratio below 70% due to yields and fees. Post-transaction, Alaris reported fair values for its Sono Bello investment: US$161.7 million as of Q1 2023 end, decreasing to reflect changes in later quarters like US$152.9 million by March 31, 2025, with realized gains of $12.5 million in Q1 2023 and ongoing unrealized adjustments. The partnership positions Sono Bello for continued expansion with support from both sponsors' capital and strategic input.
Mar 2022Undisclosed stageAlaris Equity Partners (lead)$65MSono Bello is a nationwide cosmetic surgery practice offering liposuction, body contouring, and excess skin removal procedures, with board-certified surgeons and centers certified by the Accreditation Association for Ambulatory Health Care. The company targets middle-market consumers with competitive pricing. On March 11, 2022, Alaris Equity Partners made a $65 million preferred equity investment in Sono Bello, with proceeds used to partially fund Sono Bello's acquisition of its only brand licensee, which operated 12 locations in the eastern United States and Texas. The preferred equity carried an initial annualized distribution of $8.5 million with resets beginning January 1, 2023. In February 2023, Alaris and Brookfield Special Investments completed a strategic recapitalization in which Alaris exchanged $145 million of its existing preferred equity for newly issued Sono Bello Convertible Preferred Equity and received $20.3 million in redemption proceeds, while Brookfield invested $400 million in Sono Bello Convertible Preferred Equity carrying an 8.5% annual distribution. As of September 30, 2024, Alaris valued its Sono Bello investment at $170.3 million; by December 31, 2024, the fair value was $164.8 million; and by March 31, 2025, it had declined to $152.9 million.

Who has invested in Sono Bello?

2 investors have backed Sono Bello across its funding rounds, including Alaris Equity Partners and Brookfield Asset Management.

Lead investors include Alaris Equity Partners and Brookfield Asset Management.


Sono Bello Investors

Investors in Sono Bello by funding rounds participated
InvestorHQRoundsRoleFirst check

This data is available for Pro users. Sign up to see all 2 Sono Bello investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Sono Bello Competitors

Sono Bello competitors include listed companies like AbbVie, Procter & Gamble, L'Oreal and Novo Nordisk, and private ones like Anastasia Beverly Hills and Nutrabolt.

Public and private companies comparable to Sono Bello
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
AbbVieUnited StatesUnited StatesPublicly listed$61B$17B$467B8.1x
Procter & GambleUnited StatesUnited StatesPublicly listed$87B$24B$343B4.2x
L'OrealFranceFrancePublicly listed$51B$12B$234B4.6x
Novo NordiskDenmarkDenmarkPublicly listed$48B$23B$190B4.3x
Anastasia Beverly HillsUnited StatesLos Angeles, CAPrivate--$3B-
NutraboltUnited StatesAustin, TXPrivate$650M-$2.9B4.4x

Sono Bello Public Comps

Sono Bello is still privately-owned, but its public comps include AbbVie, Procter & Gamble, L'Oreal, Novo Nordisk, Unilever, EssilorLuxottica, Colgate-Palmolive, Bayer, Hindustan Unilever and Galderma.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
AbbVie$61B$17B8.7x8.1x30.6x17.6x
Procter & Gamble$87B$24B4.2x4.2x15.4x15.6x
L'Oreal$51B$12B4.9x4.6x20.9x19.4x
Novo Nordisk$48B$23B4.2x4.3x8.8x8.8x
Unilever$58B$12B2.9x2.8x13.6x12.4x
EssilorLuxottica$33B$7.5B2.8x2.7x12.4x11.0x
Colgate-Palmolive$20B$3.9B3.8x3.6x19.8x15.2x
Bayer$52B$3.5B1.8x1.8x26.7x8.3x

This data is available for Pro users. Sign up to see all Sono Bello competitors and their valuation data.

Start Free Trial

Common questions about Sono Bello

When was Sono Bello founded?Sono Bello was founded in 2012.
Where is Sono Bello headquartered?Sono Bello is headquartered in Seattle, WA, United States.
Is Sono Bello publicly listed?No, Sono Bello is a private, VC-backed company.
How much funding has Sono Bello raised?Sono Bello has raised $611M across 2 funding rounds.
What was Sono Bello's last funding round?Sono Bello's last funding round was a $546M undisclosed-stage round in February 2023, led by Alaris Equity Partners and Brookfield Asset Management.
Who are Sono Bello's investors?Sono Bello's investors include Alaris Equity Partners and Brookfield Asset Management.
Which companies are comparable to Sono Bello?Companies comparable to Sono Bello include AbbVie, Procter & Gamble, L'Oreal, Novo Nordisk, Anastasia Beverly Hills and Nutrabolt.

See companies similar to Sono Bello

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial